Drug intelligence / Profile preview

Autologous iPSC-derived dopaminergic neural precursor cells

Development stage: Phase 1
Lead developer: XellSmart Biomedical
Modality: Cell Therapies
Administration: Intracerebral

Overview

STP-001 is a code name for an investigational cell therapy being developed by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, for the treatment of Parkinson's disease. This innovative therapy involves the transplantation of dopaminergic neural precursor cells, which are differentiated from the patient's own (autologous) induced pluripotent stem cells (iPSCs), directly into the brain. The goal is to replace the dopaminergic neurons that are progressively lost in Parkinson's disease, thereby aiming to restore motor function and alleviate symptoms. The therapy is currently in early Phase 1 clinical development.

Beyond the preview

Go deeper on Autologous iPSC-derived dopaminergic neural precursor cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Autologous iPSC-derived dopaminergic neural precursor cells.

Explore the full profile